ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
Rhea-AI Summary
ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss fourth quarter and full year 2025 financial results and business highlights.
Management will also participate in investor conferences on Feb 25, Mar 11, and Mar 22, 2026; webcasts and replay access are available via the company’s Events & Presentations page for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – SPRY
In the Feb 23 session, SPRY gained 2.33%, reflecting a moderate positive market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 03 | Earnings call notice | Neutral | -3.8% | Announced Q3 2025 earnings call timing and webcast details. |
| Aug 04 | Earnings call notice | Neutral | +1.2% | Scheduled Q2 2025 results call and provided access instructions. |
| May 05 | Earnings call notice | Neutral | -1.4% | Set date and time for Q1 2025 results and webcast. |
| Mar 03 | Earnings & conferences | Neutral | +3.2% | Announced FY 2024 call plus participation in major investor conferences. |
| Nov 06 | Earnings & conferences | Neutral | +2.6% | Outlined Q3 2024 call and multiple upcoming healthcare conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Similar conference-call and earnings scheduling headlines have historically led to relatively small, mixed price moves, with an average next-day move of about 0.37% in either direction.
Over the past year, SPRY has repeatedly announced quarterly earnings calls alongside investor conference participation. Prior notices for Q1, Q2, Q3 2025 and Q4/full-year 2024 earnings, all tagged as conferences,earnings, produced modest next-day reactions ranging from -3.79% to +3.24%, averaging about 0.37%. This pattern suggests the market typically treats these scheduling updates as routine, with limited but sometimes directional price impact around the news date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event.
In addition, ARS Pharma Management will be participating at several upcoming investor conferences:
- 10th Annual Oppenheimer Emerging Growth Conference: February 25, 2026
- Leerink Conference: March 11, 2026
A live webcast of the presentation will be available here. - 38th Annual ROTH Conference: March 22, 2026
To access the webcast and slides, please visit the Events & Presentations page in the “Investors & Media” section of the Company’s website. A replay of the webcast will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU and 优敏速® in China), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
ARS Investor Contact:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com
ARS Media Contact:
Christy Curran
Sam Brown Inc.
615.414.8668
christycurran@sambrown.com
